{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T02:39:26Z","timestamp":1761100766834},"reference-count":44,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2003,10,27]],"date-time":"2003-10-27T00:00:00Z","timestamp":1067212800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Histopathology"],"published-print":{"date-parts":[[2003,11]]},"abstract":"<jats:p><jats:bold>Aims:\u2002<\/jats:bold>To analyse systematically therapy\u2010induced lesions of haematopoiesis in chronic idiopathic myelofibrosis (IMF).<\/jats:p><jats:p><jats:bold>Methods and results:\u2002<\/jats:bold>A total of 759 sequential bone marrow (BM) biopsies (median interval 32\u2003months) were performed in 261 patients with IMF. Besides a control group (symptomatic treatment), monotherapies included busulfan, hydroxyurea and interferon. In all therapy groups hypoplasia of varying degree was a frequent finding and often accompanied by a patchy distribution of haematopoiesis. Most conspicuous was gelatinous oedema showing a tendency to develop discrete reticulin fibrosis (scleroedema). Minimal to moderate maturation defects of megakaryopoiesis and erythroid precursors occurred, but overt myelodysplastic features were most prominent following hydroxyurea and busulfan therapy. Acceleration and blastic crisis were characterized by the appearance of immature and CD34+ progenitor cells. Concerning the dynamics of fibrosis, no differences were observed between controls and the various therapy groups. In 143 patients (55%) without or with little reticulin at onset, an increase in myelofibrosis was detectable that progressed to overt collagen fibrosis.<\/jats:p><jats:p><jats:bold>Conclusions:\u2002<\/jats:bold>Therapy\u2010related bone marrow lesions in IMF comprise a strikingly variable spectrum that may include aplasia with scleroedema and a patchy distribution of myelodysplastic haematopoiesis associated with progressive myelofibrosis.<\/jats:p>","DOI":"10.1046\/j.1365-2559.2003.01732.x","type":"journal-article","created":{"date-parts":[[2004,12,25]],"date-time":"2004-12-25T17:26:51Z","timestamp":1103995611000},"page":"470-479","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Bone marrow histopathology following cytoreductive therapy in chronic idiopathic myelofibrosis"],"prefix":"10.1111","volume":"43","author":[{"given":"J","family":"Thiele","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H M","family":"Kvasnicka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Schmitt\u2010Graeff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V","family":"Diehl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2003,10,27]]},"reference":[{"key":"e_1_2_9_2_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1999.01262.x"},{"key":"e_1_2_9_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200004273421706"},{"key":"e_1_2_9_4_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00870307"},{"key":"e_1_2_9_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002770050595"},{"key":"e_1_2_9_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2900070502"},{"key":"e_1_2_9_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1991.tb01540.x"},{"key":"e_1_2_9_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0344-0338(11)80081-6"},{"key":"e_1_2_9_9_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428199609074357"},{"key":"e_1_2_9_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0950-3536(98)80036-X"},{"key":"e_1_2_9_11_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428190290021542"},{"key":"e_1_2_9_12_2","doi-asserted-by":"publisher","DOI":"10.1309\/PTVGB3DXB8A8M7KD"},{"key":"e_1_2_9_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0968-6053(05)80062-6"},{"key":"e_1_2_9_14_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V91.2.616"},{"key":"e_1_2_9_15_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428190009089438"},{"key":"e_1_2_9_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/0165-4608(90)90164-6"},{"key":"e_1_2_9_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1994.tb01303.x"},{"key":"e_1_2_9_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19950115)75:2<471::AID-CNCR2820750210>3.0.CO;2-B"},{"key":"e_1_2_9_19_2","first-page":"29","article-title":"Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival, and leukemic transition by treatment","volume":"34","author":"Murphy S","year":"1997","journal-title":"Semin. Hematol."},{"key":"e_1_2_9_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002770050536"},{"key":"e_1_2_9_21_2","first-page":"35","volume-title":"WHO classification of tumours: tumours of haematopoietic and lymphoid tissues","author":"Thiele J","year":"2001"},{"key":"e_1_2_9_22_2","first-page":"6","volume-title":"Pathology of the bone barrow.","author":"Schaefer HE","year":"1984"},{"key":"e_1_2_9_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/56.1.24"},{"key":"e_1_2_9_24_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428199609051762"},{"key":"e_1_2_9_25_2","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.43.5.365"},{"key":"e_1_2_9_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0344-0338(96)80052-5"},{"key":"e_1_2_9_27_2","first-page":"213","article-title":"Bone marrow engraftment: histopathology of hematopoietic reconstitution following allogeneic transplantation in CML patients","volume":"16","author":"Thiele J","year":"2001","journal-title":"Histol. Histopathol."},{"key":"e_1_2_9_28_2","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/j.1600-0609.1986.tb00841.x","article-title":"Therapy\u2010induced myelodysplasia and secondary leukaemia","volume":"45","author":"Frisch B","year":"1986","journal-title":"Scand. J. Haematol. Suppl."},{"key":"e_1_2_9_29_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1998.00963.x"},{"key":"e_1_2_9_30_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-8652(199602)51:2<137::AID-AJH7>3.0.CO;2-Z"},{"key":"e_1_2_9_31_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00282-997-0011-x"},{"key":"e_1_2_9_32_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428199209049817"},{"key":"e_1_2_9_33_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1992.tb01587.x"},{"key":"e_1_2_9_34_2","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.32.668"},{"key":"e_1_2_9_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0344-0338(88)80090-6"},{"key":"e_1_2_9_36_2","first-page":"593","article-title":"Progressive myelofibrosis in agnogenic myeloid metaplasia","volume":"107","author":"Lohmann TP","year":"1983","journal-title":"Arch. Pathol. Lab. Med."},{"key":"e_1_2_9_37_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401553"},{"key":"e_1_2_9_38_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002770050546"},{"key":"e_1_2_9_39_2","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1182\/blood.V65.4.803.803","article-title":"Myelofibrosis with myeloid metaplasia: pathophysiologic implications of the correlation between bone marrow changes and progression of splenomegaly","volume":"65","author":"Wolf BC","year":"1985","journal-title":"Blood"},{"key":"e_1_2_9_40_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1988.tb02507.x"},{"key":"e_1_2_9_41_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02592297"},{"key":"e_1_2_9_42_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1987.tb00762.x"},{"key":"e_1_2_9_43_2","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1600-0609.1990.tb00898.x","article-title":"Induction and maintenance alpha\u2010interferon therapy in myelofibrosis with myeloid metaplasia","volume":"52","author":"Barosi G","year":"1990","journal-title":"Eur. J. Haematol. Suppl."},{"key":"e_1_2_9_44_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428199509059658"},{"key":"e_1_2_9_45_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002770050554"}],"container-title":["Histopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2559.2003.01732.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2559.2003.01732.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2559.2003.01732.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,17]],"date-time":"2024-01-17T10:03:12Z","timestamp":1705485792000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2559.2003.01732.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,10,27]]},"references-count":44,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2003,11]]}},"alternative-id":["10.1046\/j.1365-2559.2003.01732.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2559.2003.01732.x","archive":["Portico"],"relation":{},"ISSN":["0309-0167","1365-2559"],"issn-type":[{"value":"0309-0167","type":"print"},{"value":"1365-2559","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,10,27]]},"assertion":[{"value":"2003-10-27","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}